Clinical Trial Update: Phase 1, Multiple Dose Study of MPC-6827 in Subjects With Refractory Solid Tumors [Phase 1]

View source ↗

Summary

This document reports completion of a Phase 1, multiple-dose study of MPC-6827 in subjects with refractory solid tumors.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• MPC-6827

Snippet

Sponsor: Myrexis Inc. | Conditions: Refractory Solid Tumors | Phase 1 | Status: COMPLETED